In order to investigate the generation and selection of hepatitis B virus mutants and the influence of interferon on their evolution, a longitudinal study including 22 patients was performed. The complete preS1/S2 open reading frame was analyzed by direct sequencing from serum samples obtained before and after seroconversion to anti-HBe in 11 children without ␣-interferon treatment. Furthermore, in 11 cases with therapy additional samples obtained during interferon therapy were investigated. The comparison of each patient's preS sequences analyzed before and during therapy did not show any nucleotide change, while in both groups numerous silent and missense mutations were found immediately after seroconversion. Surprisingly, in 7 cases the hepatitis B virus changed genotype from A to D (subtype adw to ayw) after seroconversion. Additional rearrangements were observed in 4 patients. In 3 cases the selection of preS2 start codon mutants was detected after seroconversion and in 1 individual a 183-nucleotide deletion was found during and after HBeAg positivity. In conclusion, the emergence of preS rearrangements and numerous base exchanges provide evidence for a strong selection process focused against the preS region. Moreover, the appearance of genotype changes after anti-HBe seroconversion reveales a thus far unrecognized event during the natural course of HBV infection in childhood.
INTRODUCTION
The hepatitis B (HBV) virus is a small, circular DNA virus with four open reading frames. It causes a variety of acute or chronic liver diseases in humans. Its envelope consists of three distinct surface proteins, the so-called large, middle, and small protein. These polypeptides are encoded by the same open reading frame, including three start codons and a common stop codon. The small or major peptide (HBsAg) is 226 amino acids in length and the middle and large proteins are assembled by amino-terminal extension of 55 amino acids (aa) of the preS2 region and of 108 to 119 amino acids (depending on the strain) of the preS1 protein, respectively (Galibert et al., 1979; Pasek et al., 1979; Valenzuela et al., 1979) .
The preS proteins play an essential role in the interaction of the immune defense to viral immune recognition sites since they contain both B-and T-cell epitopes. They were shown to provide protective immunity in chimpanzee and mice (Gerlich et al., 1990; Neurath and Thanavala, 1990; Milich et al., 1990) . The preS1 protein contains the hepatocyte-binding site (aa 21±47) and is known to be essential for virion assembly and for the transport of virions out of the hepatocyte (Ganem, 1991) .
The role of the preS2 protein is less defined. It was demonstrated to be dispensable for virion assembly, infectivity, and secretion (Fernholz et al., 1991) , but the findings are discussed controversially (Ueda et al., 1991) .
The genetic variability of the HBV genome, reflected in various genotypes and subtypes, is well established. While the HBV subtyping is based on specific amino acid residues at positions 120, 126, and 160 within HBsAg, the HBV genotypes differ by more than 8% in the protein sequence of full-length genomic comparison (Peterson et al., 1984; Okamoto et al., 1988; Ohnuma et al., 1993; Norder et al., 1992) . So far six different genotypes of the HBV designated A±F have been isolated (Okamoto et al., 1988; Norder et al., 1992) . Especially within the hypervariable preS region, the genotypes differ in numerous amino acids and some of them even in length. As in many other viruses, there is strong evidence that the principal T-and B-cell response is subtype-and genotype-specific (Cupps et al., 1993; Yamauchi et al., 1993) . Therefore it seems likely that alterations of the immune epitopes could result in a decreased efficacy of the hosts T-and B-cell response.
Recently, a number of preS1/S2 rearrangements, including deletions and initiation codon mutants, have been identified in patients with chronic and fulminant hepatitis (Fernholz et al., 1991; Santantonio et al., 1992; Uy et al., 1992; Melegari et al., 1994; Pollicino et al., 1995 Pollicino et al., , 1997 . The emergence or selection of these variants after seroconversion to anti-HBe or during interferon therapy argues for their importance to viral persistence and the clinical outcome of the disease. However, since in most of these studies the patients' HBV molecules were analyzed only in one stage of the disease, the process of sequential changes and the time and reason for their generation has not been well defined. Thus, the comparison of HBV genomes derived from HBeAg-and antiHBe-positive phases of the same carrier may lead to a better understanding of genetic heterogeneity and their biological significance.
To date there is no information about sequential changes in the preS region of the HBV genome or the incidence of deletions before and after anti-HBe seroconversion in patients who were infected in childhood. For this reason, we investigated the complete preS1/S2 region from sera of chronic HBV-infected children by direct sequencing of amplified HBV DNA. Furthermore, the effect of interferon treatment on the selection of mutants was evaluated by comparing the sequential changes of 11 treated with 11 untreated patients.
RESULTS
Comparison of the preS1/S2 ORF to the reference sequences Figure 1 illustrates all missense mutations, deletions, and preS2 start codon mutations in comparison to the reference sequences. The patients infected with genotype A showed the highest homology to the reference sequence isolated by Valenzuela et al. (1979) , while subjects carrying HBV of genotype D were most similar to the reference of Galibert et al. (1979) . In one patient a 183-bp deletion and in three children preS2 start codon mutations were detected. Moreover, numerous amino acid changes were found in all subjects. There were several regions with a higher frequency of mutations. In children with genotype D a small region of seven amino acids (aa 35±41) at the C terminal of preS2 displayed many changes in all chronic carriers. In genotype A isolates many missense mutations could be identified especially in the middle of preS1 and at the very C terminal of the preS2 ORF. Within the hepatocyte binding site (aa 21±47) the number of missense mutations was low. No relation was found between the number or the position of missense mutations and histological inflammatory activity.
Sequential changes after seroconversion
The sequential changes of each case after seroconversion to anti-HBe are summarized in Fig. 2 . The most striking finding was that 7 patients (P, Q, R, S, T, U, and V) changed HBV genotype after anti-HBe seroconversion. Moreover, all 7 patients belonged to the group of 11 children who seroconverted spontaneously without having received ␣-interferon (IFN) treatment. No genotype replacement was observed in patients with interferon therapy. Patients F, G, and I were already infected with genotype D strains in the presence of HBeAg. The 7 subjects changed from subtype adw of genotype A to subtype ayw of genotype D. As demonstrated in Fig. 4 all patients showed a mixed population of genotypes A and D, which can be detected as a double band differing in 33 nucleotides in the agarose gel due to the lack of 11 amino acids at the amino terminal of the preS1 ORF in most HBV genomes of genotype D. Interestingly, genotype D always predominated significantly over genotype A. Sequencing of the additional six serum samples of subjects S, T, and U confirmed that the genotype replacement always correlated with the emergence of antibodies against the e protein, as in none of these patients genotype changes were detected in the presence of HBeAg, while the mixed HBV genotype population persisted after seroconversion (data not shown).
Since the existence of HBV mixed particles containing genes related to different HBV genotypes has been reported, the precore/core gene from three patients with genotype replacements (patients S, T, and U) was analyzed. From each child one HBeAg-positive serum sample and one anti-HBe-positive sample was amplified and sequenced.
Both the precore and the core sequences showed genotype A-related nucleotides in the presence of HBeAg. After anti-HBe seroconversion the precore genotype-related nucleotides at positions 1850 and 1858 changed from 1850 A /1858 C (genotype A) to 1850 T /1858 T (genotype D).
The HBV core gene of genotype D differs in a 6-nucleotide deletion to genotype A. This deletion could be identified in all three patients only after anti-HBe seroconversion. Therefore it seems likely that the isolated viruses after seroconversion are full-length HBV genomes of genotype D.
The high number of aa substitutions in patients who changed the genotype, illustrated in Fig. 2 , is mostly due to genotype-related differences in the amino acid sequence. Most of the serum samples of these patients are obtained between 12 and 48 months after seroconversion. However, in cases S and T a heterogeneous viral population of genotypes A and D was already observed 1 month after the appearance of anti-HBe.
Numerous silent and missense mutations were identified in 19 cases. These mutations frequently resulted in alteration of immunological target sites since many T-and B-cell epitopes have been described so far within the preS region (illustrated at the bottom of Fig. 2 ), (Neurath et al., 1989; Milich, 1988; Ferrari et al., 1992) .
Only patients B, C, F, and L, from whom the HBV DNA was analyzed immediately after seroconversion, presented no change within the preS1/S2 region after the emergence of antibodies against the HBe antigen.
Additional preS rearrangements
In one child (patient F) in the amplified sera before and after anti-HBe seroconversion the agarose gel revealed, besides the expected band, a second smaller amplification product. The amplified HBV DNA was then subcloned. Six of 18 clones were consistent with a deletion and 12 showed wildtype length. The sequence analysis of the smaller fragment revealed a 183-nt in-frame deletion at the C-terminal of preS1 in all 6 clones. Amplification of additional samples revealed that the preS1 deletion mutant became visible even before ␣-interferon therapy was started (data not shown).
In three other children important changes were registered. In patients K and O the preS2 start codon mutated from ATG to ACG and in patient N to ATA, resulting in nonexpression of the preS2 protein.
The sensitivity of direct sequencing to detect minor populations, which is approximately 10%, allowed us to identify the coexistence of HBV strains with wildtype and mutated preS2 start codons. Quantification of the heterogeneous viral population according to Leitner et al., (1993) revealed a wildtype:variant ratio of roughly 1:3 in the presence of HBeAg. After anti-HBe seroconversion the preS2-defective particles predominated clearly, in a ratio of 4:1.
Frequency of base exchanges
Figure 2 presents the number of missense mutations after anti-HBe seroconversion in all 22 children. No cluster or hot spot of mutations could be registered.
The complete preS ORF was investigated 1 to 48 months after seroconversion. In Fig. 3 the number of nucleotide substitutions after seroconversion is shown in relation to the time after seroconversion. The rapid emergence of nucleotide changes immediately after seroconversion is reflected in patients I, J, and G, where within the first 2 months one to three exchanges could be identified. This is not the case in four other subjects (B, C, F, and L), in which no sequential differences were observed. Altogether it is remarkable that the number of nucleotide substitutions is increasing with the time after seroconversion. For example, among patients B, C, F, L, and I, who were investigated 1 month after seroconversion, only one case showed one nucleotide exchange. This is quite in contrast to patients analyzed more than 1 year after emergence of anti-HBe, where 3 to 25 base exchanges could be detected (patients O, A, D, E, and K; see Fig.3 ). Nucleotide exchanges in patients L±V are not shown, since most of the changes after seroconversion are due to the genotype change.
Mutations in patients with and without ␣-interferon
As shown in Fig. 1 no significant difference in the number or position of mutations was observed between patients with ␣-interferon therapy in comparison to patients without treatment. PreS2 start codon mutants were identified in two children without interferon treatment and in one case with interferon-induced seroconversion. The preS1 deletion emerged in a patient with interferon therapy but the selection process had already started before the initial dose of ␣-interferon was given. However, it was remarkable that none of the seven patients with HBV genotype changes did receive ␣-interferon.
DISCUSSION
In the present study, we have analyzed the HBV preS region in the high replicative HBeAg-positive phase and the low replicative anti-HBe-positive phase. Anti-HBe seroconversion occurred either spontaneously or after ␣-interferon treatment. Numerous base exchanges and rearrangements were identified. However, the most striking finding was the frequent change of genotype A to D (subtype adw to ayw) in children with spontaneous conversion to anti-HBe. This was in contrast to individuals with interferon-induced seroconversion, where in none of them a genotype replacement was observed. This might have happened incidentally since we had also identified genotype changes in some patients with interferon therapy (Bahn et al., 1997) . Although in most of the children the period between seroconversion and time of sequencing was more than 16 months, the emergence of genotype D strains 1 month after anti-HBe seroconversion in two patients (S and T) argues for a rapid selection process triggered by the increased immunological activity resulting in antibodies against the e antigen. Sequencing of only one sample during HBeAg positivity will fail to detect genotype changes during this serological state. Therefore, six additional serum samples from patients S, T, and U were investigated. The results confirmed that only after anti-HBe seroconversion can a genotype change be observed. Moreover, the coexistence of genotypes A and D persisted in all patients, similar to what is presented in Fig. 4 .
We tried to find the meaning of the appearance of other genotypes. The transition from an relative immune tolerant state to activation of the immune system with generation of antibodies against HBeAg results in a strong selection pressure on the viral genomes. Since the preS region is highly immunogenic at the T-and B-cell level, mutations causing changes of immune target sites such as T-and B-cell epitopes could lead to escape of the virus from immune clearance. This effect could be established directly or indirectly through reduced binding affinity of antibodies or by MHC class I-mediated presentation of modified oligopeptides on the cell surface of hepatocytes, respectively. It is conceivable that these effects are reached by changing the genotype because they differ in numerous amino acids in the preS ORF. This theory is supported by the observation that the T-and B-cell response is mostly subtypespecific (Milich et al., 1990) .
In our understanding the prerequisite for a genotype change would be a simultaneous infection with different genotypes. Since the evolution of a new genotype within such a short period of time seems to be very unlikely, only patients harboring at least two different HBV genotypes within their heterogeneous viral pool at the time of infection would have the chance to select another one under certain immunological conditions. Moreover, our results suggest that these selected genotypes are not only present in the preS region. The precore and core regions showed genotype A-related sequences in the presence of HBeAg, whereas after anti-HBe seroconversion in all subjects genotype D-specific nucleotide exchanges and the genotype D-related 6-nucleotide deletion in the core gene was found. For this reason it appears that HBV particles of full-length genotype D were selected after seroconversion.
To our knowledge this is the first study that provides proof of genotype changes during the natural course of HBV infection. However, two further studies support our findings. Gu Ènther et al., (1992) found after anti-HBe seroconversion point mutations within the preC region in patients who were mostly specific for HBV strains of genotype D. In the same patients they were absent in the HBeAg-positive phase. In addition, Li et al. (1993) detected in most subjects genotype A during HBeAg positivity, whereas in another population of patients who had already seroconverted to anti-HBe mostly viral strains of genotype D were found. Taken together with our own results these data suggest that HBV genotype changes in adulthood are also a frequent event after anti-HBe seroconversion.
Furthermore, numerous missense and silent mutations in the preS1/S2 region were identified after antiHBe seroconversion. One important cause of the generation of mutations in HBV is the lack of a proofreading activity of the DNA polymerase protein (Coffin, 1986; Dougherty and Temin, 1988) . Okamoto et al. (1987) reported the emergence of only 11 nucleotide substitutions in a chronic HBV carrier after 54 years of infection. Thus, the evolutionary rate of genetic changes in the HBV genome was estimated to be approximately 4.6 ϫ 10
Ϫ5
per site per year (Okamoto et al., 1987; Orito et al., 1989) . However, this natural mutation rate is much smaller than the rate of mutations found in our patients after seroconversion, probably due to the above-mentioned mechanism of enhanced immunological pressure on the HBV genomes during the process of anti-HBe seroconversion. A T-or B-cell-dependent viral selection process has not yet been proven. Nevertheless, the high mutation rate after conversion and the finding that many of the changes occurred in immune epitopes so far recognized supports the idea of the biological significance of emerging HBV variants, particularly within the core, preS, and surface ORFs, which have all been described as containing immune epitopes.
Recently, preS2 start codon mutants have been described in chronic HBV carriers (Santantonio et al., 1992; Gerken et al., 1991; Fernholz et al., 1991; Pollicino et al., 1997) . Due to a point mutation or to deletions these mutant genomes are unable to express the preS2 protein. All of the preS2-defective genomes were found in the presence of anti-HBe. In our investigation, three patients had start codon mutations. Since there is increasing evidence that the preS2 proteins are not essential for virion assembly, infectivity, and secretion (Fernholz et al., 1991; Pollicino et al., 1997) the virus is able to dispense with it. It was demonstrated that a major B-cell epitope is located at the amino terminal of this region (Neurath and Thanavala, 1990) . Therefore, it is conceivable that under the condition of increased immune pressure of the anti-HBe seroconversion process the advantage of getting rid of preS2 proteins could exceed the benefits of producing it. Interestingly, in one patient a mutant/wildtype coexistence was detected both in the   FIG. 4 . Genotyping by size polymorphism of the preS region. Shown are the seven patients (P±V) with genotype changes. For each subject two panels with PCR products before (1) and after (3) anti-HBe seroconversion are demonstrated. The expected amplification fragments were 588 nt for genotype A and 555 nt for genotype D.
HBeAg-positive phase and after seroconversion. However, this theory is underlined by the fact that the ratio of the mixed population shifted significantly to a wildtype presence of only around 20% after anti-HBe seroconversion, while during the HBeAg-positive phase the wildtype predominated clearly, with approximately 75% over mutant preS2 start codon molecules. Santantonio et al. (1992) suggested that the generation of preS2-defective mutants was triggered by IFN treatment. In view of our results this seems unlikely. Two of three children with preS2 start codon mutants were not treated with IFN.
In one of our patients a hepatitis B virus lacking 183 bases in the preS1 region emerged during the course of infection. The fact that this mutation has been found in a number of chronically HBV-infected patients (Gerken et al., 1991; Seminago et al., 1993; Takayanagi et al., 1993; Nakajima et al., 1994; Melegari et al., 1994) supports the idea that it does not occur randomly but is due to donor and acceptor splice sites. One important consequence of the deletion is the removing of the promoter of the small envelope protein. Therefore, the preS1-deleted genomes are no longer able to produce HBsAg (Melegari et al., 1997) . In addition, Melegari et al. (1997) found that the 183-nt deletion HBV genomes were retained with the cytoplasm. Only after coexpression with the small envelope protein could the mutant genomes be secreted into the cell supernatant. This finding explains why the deleted variant was always accompanied by HBV genomes of wildtype length. In contrast to all other cases reported with the same mutation, in our patient the deletion was detected even before IFN treatment was started and thus, the selection of this mutant must have other causes than the use of IFN.
In conclusion, our data indicate that the appearance of antibodies against the e antigen results not only in increased immunological pressure against the e protein and consequently the preCore region. The generation of preS mutations and rearrangements after anti-HBe seroconversion suggests a selection process that is also concentrated against the preS ORF.
Especially surprising was the finding of HBV genotype replacements. This may induce a change in the antigenic masc, which the virus presents to the immune system, as HBV genotypes differ in numerous amino acids and therefore would lead to altered T-and B-cell target sites. The consequences and mechanisms of these selections have to be clarified in further studies.
MATERIALS AND METHODS

Patients
Sera of 22 children with chronic active hepatitis (CAH), chronic persistent hepatitis (CPH), or minimal hepatitis (MH), according to the criteria of de Groote et al. (1968) , were collected from different stages of the disease with a median followup of 40 months (clinical and laboratory data are shown in Table 1 ). Patients A±K were treated with ␣-IFN and three different serum samples before seroconversion to anti-HBe, during interferon therapy, and after seroconversion were obtained from each subject. In the second group patients L±V seroconverted spontaneously to anti-HBe. Two serum samples were taken before and after seroconversion to anti-HBe. All samples were HBsAg positive.
The sera of the 7 patients with genotype replacements have been collected in four different hospitals in Germany. None of these infants was related to any of the other patients included in this study. Furthermore, to our knowledge none of these 7 children received blood at any time. Therefore, an epidemiological link among them seems unlikely. Most of them were infected perinatally with HBV.
To further evaluate the process of genotype changes during chronic hepatitis, 6 additional serum samples obtained both during the presence of the e Ag and after the appearance of anti-HBe from 3 patients with genotype changes (patients S, T, and U) were sequenced.
Serological markers
HBsAg, HBeAg, anti-HBe, anti-HBs, and anti-HBc were assayed using commercial radioimmunoassays (Abbott Laboratories, North Chicago, IL). All patients were negative for antibodies to hepatitis C virus, hepatitis D virus, and human immunodeficiency virus. HBV DNA was determined quantitatively by a liquid hybridization assay (Hybride Capture Systems, Digene Diagnostics, Beltsville, MD).
PCR amplification, subcloning, and sequencing
An aliquot of 200 l of each patient's serum was obtained to isolate viral DNA with the QIAamp Blood Kit (Qiagen, Chatsworth, CA). The DNA was eluted with 50 l distilled water according to the manufacturer's recommendations. The preS1/S2 open reading frame was amplified by PCR in 50 l of buffer containing 300 mM Tris±HCL (pH 8.5), 75 mM (NH 4 ) 2 SO 4 , 1.0 mM MgCl 2 , 400 mM deoxynucleoside triphosphates (dNTPs), 1 U of Taq polymerase (Boehringer Mannheim, Germany), and 30 pmol each of primers P1 and P2 (P1, 5Ј-GGG TCA CCT TAT TCT TGT-3Ј, nucleotides 2816±2833; P2, 5Ј-GTC CTA GGA ATC CTG ATG-3Ј, nucleotides 173±189). The PCR was performed for 35 cycles at 94°C for 1 min, 58°C for 30 s, and 72°C for 1 min in a thermal cycler (Perkin± Elmer Cetus, Norwalk, CT). The PCR products were visualized after electrophoresis in a 2% agarose gel and with ethidium bromide staining. In order to minimize artificial mutagenesis for samples not detectable after the first amplification, a second PCR was performed with 30 cycles; 1 U Taq DNA±Pwo DNA polymerase (Expand High Fidelity assay; Boehringer Mannheim) was used. In contrast to the Taq enzyme, the Pwo polymerase has a proofreading activity. To evaluate whether only the preS regions demonstrate genotype D-related changes in patients with genotype replacements, the precore/core gene was amplified and sequenced from patients S, T, and U as described above with the following primers: precore region (P3, 5Ј-TGT CAA CGA CCG ACC TTG AG-3Ј, nucleotides 1681±1700; P4, 5Ј-CAA TGC TCA GGA GAC TCT AAG GC-3Ј, nucleotides 2043±2021); core region (P5, 5Ј-TTT TTC ACC TCT GCC TAA TCA-3Ј, nucleotides 1821±1841; P6, 5Ј-TTG GGA TTG AAG TCC CAA TCT GG-3Ј, nucleotides 2957±2935).
The amplified preS1/S2 ORF of patient F and of patients with genotype changes after anti-HBe seroconversion were inserted by blunt-end ligation into a ECO RV-digested Bluescript plasmid (Stratagene). The recombinant plasmids were introduced in Escherichia coli DH5 a (BRL) and cloned. One clone of wildtype and six clones of deleted length were sequenced from patient F. In patients with genotype changes only one clone of genotype D length was sequenced, reflecting the major population after anti-HBe seroconversion (see Fig. 4 ).
Plus and minus strands were sequenced with primers P1 and P2 using a Dye Terminator Cycle Sequencing Kit (ABI PRISM, Foster City, CA) in an automated sequencer, Model 377 (ABI).
Analysis of sequences and genotyping
According to sequence alignments with previously published HBV genomes (for genotypes A±F, Galibert et al., 1979; Pasek et al., 1979; Valenzuela et al., 1979; Bichko et al., 1985; Tong et al., 1990; Sastrosowignijo et al., 1987; Okamoto et al., 1987; Fujiyama et al., 1983; Vaudin et al., 1988) , the HBV strains were classified to the non-Asian genotypes A or D. In addition, sequence data of each patient were compared with each other. Sequence alignments were performed using the Sequencher 3.0 software program.
